Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium bifidum triple viable powder
- Development stage
- Unknown
- Lead developer
- Jincheng Haisi Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium bifidum triple viable powder is a live biotherapeutic product (LBP) consisting of a combination of three probiotic bacterial strains: *Bifidobacterium bifidum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. Registered as a pharmaceutical drug in China, it is primarily indicated for the treatment of intestinal dysbiosis and associated gastrointestinal disorders such as diarrhea, constipation, and enteritis. The formulation works by replenishing beneficial gut flora, inhibiting the growth of pathogenic bacteria through the production of organic acids (lactic and acetic acid), and enhancing the intestinal mucosal barrier. In the context of pediatric colonic Crohn's disease, it is being investigated as an adjunctive therapy to infliximab induction to improve mucosal healing and clinical remission rates by modulating the gut microbiome and reducing local inflammatory responses.
- Other names
- Bifidobacterium bifidum, Lactobacillus acidophilus, and Enterococcus faecalis triple viable powderBifidobacterium triple viable powder双歧杆菌三联活菌散
Beyond the preview
Go deeper on bifidobacterium bifidum triple viable powder.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium bifidum triple viable powder.